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ABSTRACT
A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from 
a striated muscle was previously orthotopically implanted in the right biceps femoris 
muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nude-
mouse model. In the present study, two weeks after orthotopic transplantation of the 
UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) 
or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated 
weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed 
and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 
2208.3 mm3; CDDP (G2): 841.8±3 mm3, p=0.0001; DOX (G3): 693.1±3 mm3, p=6.56E-7; 
3Pt (G4): 333.7±1 mm3, p=4.8E-8. 3Pt showed significantly more efficacy compared to 
other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal 
deaths in any of the four groups. The present results suggest 3Pt is a promising new 
candidate for UPS since it was demonstrated to be effective in a PDOX model.
INTRODUCTION
Our laboratory pioneered patient-derived orthotopic 
xenograft (PDOX) mouse models  of cancer using surgical 
orthotopic implantation (SOI). PDOX models are patient-
like, in contrast to the ectopic subcutaneous-transplant cancer 
models [1]. In a previous study, a patient with high-grade 
undifferentiated pleomorphic soft-tissue sarcoma (UPS) from 
a striated muscle was transplanted orthotopically in the right 
biceps femoris muscle of mice to establish a UPS PDOX 
model. Histological analysis indicated tumor eradication only 
when mice were treated with tumor-targeting S. typhimurium 
A1-R followed by doxorubicin (DOX) [2].
We previously developed a novel platinum 
complex, 3Pt. 3Pt comprises anionic-phosphate 
moieties. The cytotoxic potency of 3Pt was greater 
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than that of cisplatinum (CDDP) in all osteosarcoma 
cell lines tested. 3Pt was not cross resistant in CDDP-
resistant cells [3].
In the present study, we determined the efficacy of 
3Pt against the UPS PDOX model for comparison to DOX 
and CDDP.
RESULTS AND DISCUSSION
Drug efficacy
The novel anionic-phosphate-platinum complex 3Pt 
(Figure 1) was evaluated in the schema shown in (Figure 2). 
Two weeks after orthotopic implantation, UPS tumors grew 
to 5 mm in diameter in PDOX nude-mouse models. Thirty-
two PDOX mice were randomized into 4 groups: untreated 
controls; DOX; CDDP; and 3Pt. Treatments were repeated 
once a week for 3 weeks. Six weeks after transplantation, 
all mice were sacrificed. At 6 weeks, treatment of the UPS 
PDOX with 3Pt resulted in the largest decrease in tumor 
volume relative to untreated controls compared to DOX or 
CDDP: Control (G1): 2208.3 mm3; CDDP (G2): 841.8 mm3, 
p=0.0001; DOX (G3): 693.1 mm3, p = 6.56E-7; 3Pt (G4): 
333.7 mm3, p = 4.8E-8. 3Pt showed significantly more efficacy 
compared to CDDP (p = 0.0002) or DOX (p = 0.001) (Figures 
3, 4). There were no animal deaths in any of the four groups. 
Body weights of the treated mice were not significantly 
different from untreated controls in any group (Figure 5).
Figure 1: Chemical structure of the novel platinum compound 3Pt.
Figure 2: Treatment schema.
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Figure 3: Efficacy of cisplatin (CDDP), doxorubicin (DOX), and 3Pt on the UPS PDOX nude-mouse models. DOX (3 
mg/kg, i.p., qw×3); CDDP (6 mg/kg, i.p., qw×3); 3Pt (41.1 mg/kg, i.p., qw×3). Tumor volume was measured at the indicated time points 
after the onset of treatment. n=8 mice/group; * p < 0.005, ** p<0.0001.
Figure 4: Efficacy of CDDP, DOX and 3Pt on the UPS PDOX. Photographs of representative PDOX nude-mouse models in each 
treatment group at the end of the treatment period.
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Figure 5: Body weight of treated and untreated mice. Bar graphs show body weight in each group at pre-treatment and 4 weeks 
after drug administration.
Figure 6: Tumor histology. (A) Hematoxylin and eosin (H&E)-stained sections of the original patient tumor. (B) Untreated UPS PDOX 
tumor. (C) UPS PDOX tumor treated with CDDP. (D) UPS PDOX tumor treated with DOX. (E) UPS PDOX tumor treated with 3Pt. Scale 
bars: 80 μm.
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Histology of original tumor and implanted 
tumors
A high-power photomicrograph of the original patient 
tumor hematoxylin and eosin (H&E)-stained section showed 
solid sheets of cancer cells by various shapes, including 
spindle-shaped, round-shaped with hyperchromatic, 
enlarged nuclei as well as bizarre multinucleate giant cells. 
Numerous mitotic figures, including atypical forms are 
present (Figure 6A). The high-power view of the H&E 
section of the untreated PDOX tumor had similar features 
including spindle-shaped cells and round-shaped cells. 
Numerous mitotic figures, including atypical forms are also 
present (Figure 6B). PDOX tumors treated with CDDP were 
comprised of various shaped viable cells without apparent 
necrosis (Figure 6C). PDOX tumors treated with DOX had 
viable cells with little necrosis (Figure 6D). The 3Pt-treated 
PDOX tumor showed apparent necrosis and fibrosis (Figure 
6E).
MATERIALS AND METHODS
Animal care
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
Animals were housed in a barrier facility on a high 
efficiency particulate arrestance (HEPA) - filtered rack 
under standard conditions of 12-hour light/dark cycles. 
The animals were fed an autoclaved laboratory rodent diet. 
All animal studies were conducted with an AntiCancer 
Institutional Animal Care and Use Committee (IACUC)-
protocol specifically approved for this study and in 
accordance with the principals and procedures outlined 
in the National Institutes of Health Guide for the Care 
and Use of Animals under Assurance Number A3873-1. 
In order to minimize any suffering of the animals the use 
of anesthesia and analgesics were used for all surgical 
experiments. Animals were anesthetized by subcutaneous 
injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 
mg/kg xylazine, and 0.48 mg/kg acepromazine maleate. 
The response of animals during surgery was monitored 
to ensure adequate depth of anesthesia. The animals 
were observed on a daily basis and humanely sacrificed 
by CO2 inhalation when they met the following humane 
endpoint criteria: severe tumor burden (more than 20 
mm in diameter), prostration, significant body weight 
loss, difficulty breathing, rotational motion and body 
temperature drop.
Patient-derived tumor
A 64-year-old male diagnosed with high-grade 
undifferentiated pleomorphic sarcoma (UPS) on his right 
high thigh previously underwent surgical resection at the 
Department of Surgery, University of California, Los 
Angeles (UCLA), under written informed consent and IRB 
approval (IRB #10-001857). The patient did not receive 
any chemotherapy or radiotherapy prior to surgery. A part 
of the resected specimen, designated as PDOX1, was sent 
to our laboratory right after surgery and implanted in nude 
mice [2, 4].
Drugs
The novel platinum drug, 3Pt (Figure 1) was 
synthesized as previously described [3]. CDDP and DOX 
were purchased from Teva Parenteral Medicine, Inc. 
(Irvine, CA).
Surgical orthotopic implantation (SOI) for 
establishment of the PDOX model
After subcutaneous growth of the patient tumor 
in nude mice, it was harvested and divided into small 
fragments (3-4 mm) for orthotopic transplantation in nude 
mice. After the nude mice were anesthetized, a 5 mm skin 
incision was made on the right high thigh. The biceps 
femoris was then split to make space for a tumor fragment. 
A single tumor fragment was implanted orthotopically into 
the space to establish a PDOX model. The wound was 
closed with 6-0 nylon suture (Ethilon, Ethicon, Inc., NJ, 
USA).
Treatment study design
Two weeks after orthotopic implantation, tumors 
reached 5 mm in diameter. Thirty-two UPS PDOX mice 
were randomized into 4 groups (Figure 2): G1: control 
without treatment (n=8); G2: cisplatin (CDDP) (6 mg/kg), 
intraperitoneal (i.p.) injection, weekly for 3 weeks) (n=8); 
G3: Doxorubicin (DOX) (3 mg/kg, i.p. injection, weekly 
for 3 weeks) (n=8); G4: 3Pt (41.1mg/kg), i.p. injection, 
weekly for 3 weeks) (n=8). Tumor length, width, and 
mouse body weight were measured once a week. Tumor 
volume was calculated with the following formula: Tumor 
volume (mm3) = length (mm) × width (mm) × width (mm) 
× 1/2. Data are presented as mean ± SD. All treated mice 
were sacrificed after 6 weeks and tumors were resected for 
histological analysis (please see below).
Histology
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (3 μm) were deparaffinized in xylene 
and rehydrated in an ethanol series. H&E staining was 
performed according to a standard protocol. Histological 
examination was performed with a BHS system 
microscope. Images were acquired with INFINITY 
ANALYZE software (Lumenera Corporation, Ottawa, 
Canada).
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Statistical analysis
Data are presented as means±standard deviation 
and were compared between groups using the unpaired 
Student’s t-test. A p<0.05 value was considered 
statistically significant.
CONCLUSION
In the present study, we compared a novel anionic-
phosphate-platinum compound; 3Pt, with CDDP and 
DOX against an UPS PDOX nude mouse model. 3Pt 
showed significantly more efficacy compared to CDDP 
(p=0.0002) or DOX (p=0.001) which are first-line 
therapy for this disease. 3Pt is a promising candidate 
for UPS since it was effective in a PDOX model. Future 
studies will combine 3Pt with other drugs on UPS 
and other sarcoma PDOX models in order to identify 
regimens which eradicate tumors and are therefore of 
high potential in the clinic.
Toward the goal of personalized, precision 
oncology, our laboratory pioneered the patient-derived 
orthotopic xenograft (PDOX) nude mouse model with 
the technique of surgical orthotopic implantation (SOI), 
including pancreatic [5–8], breast [9], ovarian [10], lung 
[11], cervical [12], colon [13–15], stomach [16], sarcoma 
[2, 17–20] and melanoma [21–24]. The present manuscript 
demonstrates the precision with which the UPS PDOX 
model distinguishes responses to CDDP, DOX, and 3Pt.
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [25–30].
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